Patent – Infringement. The defendant company, Lilly, produced a cancer treatment marketed under the name Alimta. The claimant companies sought to produce a generic product and obtain regulatory approval for it by reference to Alimta. Lilly contended that doing so would infringe its patent. The Patents Court considered the issue with regard to the United Kingdom, France, Italy and Spain, and held that the claimant companies were entitled to a declaration of non-infringement concerning all of the jurisdictions in question.